Wegener's Granulomatosis Clinical Trial
Official title:
Activating Receptors and DAP12 Protein in Wegener's Granulomatosis
The investigators recently showed an abnormal expansion of NK-like CD4+ T cells in Wegener's granulomatosis (WG), mainly in the diffuse vasculitis presentation. These cells expressed an assortment of activating NK cell receptors and their signaling partners, in particular DAP12. The investigators hypothesize that DAP12, or a downstream signaling target of DAP12, is the missing link between the different cell components involved in WG (neutrophils, macrophages, CD4 T cells).
The investigators will test our hypothesis of "DAP-12 gain-of-function" by quantitative (mRNA and protein) and qualitative (DNA, signaling and cellular activation) analysis of the DAP12 signaling pathway in WG patients with localized (group 1; n=30) or diffuse WG (group 2; n=30) by comparison with patients with micro polyangitis (group 3; n=30), or with sarcoidosis ( group 4; n=30), and healthy blood donors (group 5; n=30). Blood samples will be collected during a routine medical visit. These results may help to design future therapeutic strategies based on modulation of specific intra-cellular pathways involved in the disease. ;
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT00747461 -
Interventional Cryotherapy for the Eradication of Benign Airway Disease ("ICE the BAD")
|
Phase 4 | |
| Completed |
NCT00072592 -
An Open Label Pilot Study Examining the Use of Rituximab in Patients With Wegener's Granulomatosis Who Have Experienced Disease Relapse on Standard Therapies
|
Phase 1 | |
| Recruiting |
NCT02593565 -
Vasculitis Pregnancy Registry
|
||
| Completed |
NCT00307593 -
RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides
|
N/A | |
| Active, not recruiting |
NCT00006055 -
Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases
|
N/A | |
| Completed |
NCT00001473 -
Cyclophosphamide and Prednisone Followed by Methotrexate To Treat Vasculitides
|
N/A | |
| Terminated |
NCT01408836 -
Plasma Exchange for Renal Vasculitis
|
Phase 2/Phase 3 | |
| Completed |
NCT00001256 -
Steroids and Methotrexate to Treat Systemic Vasculitis
|
Phase 2 | |
| Completed |
NCT00040248 -
Daclizumab to Treat Wegener's Granulomatosis
|
Phase 2 | |
| Completed |
NCT00005007 -
Etanercept for Wegener's Granulomatosis
|
Phase 2/Phase 3 | |
| Completed |
NCT00307671 -
Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years
|
Phase 4 | |
| Completed |
NCT01988506 -
Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases
|
Phase 2 | |
| Recruiting |
NCT01066208 -
American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic Vasculitis
|
N/A | |
| Completed |
NCT00104299 -
Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis
|
Phase 2/Phase 3 | |
| Completed |
NCT00753103 -
Anti-Cytokine Therapy for Vasculitis
|
Phase 2 | |
| Completed |
NCT02176070 -
Reproductive Health in Men and Women With Vasculitis
|
N/A | |
| Completed |
NCT00468208 -
Abatacept in Treating Adults With Mild Relapsing Wegener's Granulomatosis
|
Phase 1/Phase 2 | |
| Completed |
NCT00004567 -
Comparison of Treatments to Maintain Disease Remission in Patients With Wegener's Granulomatosis and Related Vasculitis Syndromes
|
Phase 2 | |
| Completed |
NCT00001901 -
Etanercept to Treat Wegener's Granulomatosis
|
Phase 2 | |
| Completed |
NCT00430105 -
Pulse Versus Continuous Cyclophosphamide for Induction of Remission in ANCA-Associated Vasculitides
|
Phase 2/Phase 3 |